In our last series of articles we talked about the three different line of treatment for OAB patients. By now, we know that there are several treatments for those suffering from the condition, but they still do not work for a significant part of the population. Most patients suffer from several side effects, that can be very painful and/or uncomfortable. At Inura, we aim to revolutionize the treatment for OAB patients. With our first-of-a-kind urethral ovulum, we want to give OAB patients a comfortable and permanent solution to their condition while also improving their quality of life.

Millions of people, especially women, suffer in silence every day from Overactive Bladder (OAB). This condition causes patients to have debilitating and disturbing symptoms, which prevents them from having personal, social, and professional normal lives.

While there are different treatment options for OAB, from behavioral intervention, oral medication until very invasive procedures, they are still not guaranteed to work for every patient and many have very uncomfortable side effects.

Considering the quality of life of OAB patients and based on extensive scientific research, Inura has developed the first-of-a-kind, easy-to-use urethral ovulum. The ovulum was developed considering the female urethral anatomy, and ensures an easy insertion performed by the patient. The ovulum enables local delivery of the active pharmaceutical ingredient to the urinary tract, which after insertion will slowly melt down during a 10 to 15 minutes period, releasing the medication locally and avoiding major side effects. It is expected to provide patients a quick relief that can last up to 8 hours, allowing OAB patients to have a full night of sleep, thereby, improving their quality of life.

Inura’s ovulum aims to deliver oxybutynin to the site of action, the bladder. Oxybutynin has been in the market for decades now, being used as an oral and transdermal therapy, and it is proved to work efficiently for the condition. This novel route of administration, developed by Inura, is designed to minimize the side effects associated with the currently available treatments. It is a rescue therapy achieved by targeting the site of the problem, the urinary bladder.

The ovulum is a reliable solution for OAB patients, and it enables the drug to act directly on the bladder muscle, improving the symptoms of the condition. As the medication is locally administrated it leads to less absorption of the medicament by the blood and subsequently less to no side effects. The ovulum is designed to provide OAB patients with a better quality of life at a very competitive price compared to other medications available on the market.

Inura’s patented technology has the potential to revolutionize patient’s quality of life, suffering with the condition, and help them live full normal lives.

About Inura Medical

Inura Medical is a Swiss start-up company with a clear vision to make a difference in women’s health. Inura’s product is an innovative, first-of-its-kind “intraurethral ovulum” that utilizes a novel route of drug administration to treat diseases of the bladder and lower urinary tract. The first indication we are addressing is a chronic disease, named overactive bladder (OAB). We are located in the HEMEX incubator in Liestal, Switzerland. Inura Medical’s technology results from decades of work in urology by Professor S. Grant Mulholland from Jefferson Medical College, Pennsylvania (US). Professor Mulholland was a renowned surgeon, academic, and past President of the American Urology Association. More details on https://inuramedical.ch/.